Latest Breaking News On - Qualified infectious disease product - Page 11 : comparemela.com

CorMedix Inc Announces Commercial and Operational Updates

CorMedix Inc Announces Commercial and Operational Updates
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Dan ferrymanaging directorlifesciJoseph todiscoSecurities exchangeCormedix incMedicaid servicesTransitional drug add on paymentMedicare partAccount managersFast trackQualified infectious disease productNew drug applicationPrivate securities litigation reform actSecurities actSecurities exchange actDan ferrymanaging directorlifesci advisors

Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections

Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomLora grassilliTed jenkinsSath shuklaExchange commissionAdministration for strategic preparednessHealth media relationsDevelopment authorityMeiji seika pharma coUs department of healthTebipenem hbr researchHuman servicesBiomedical advanced researchDrug administrationZeno group

Spero Therapeutics Announces First Patient, First Visit for

$95 million in development milestones payable over two years, as part of GSK license agreement.

United statesUnited kingdomLora grassilliSath shuklaTed jenkinsTebipenem hbr researchUs department of healthExchange commissionHealth media relationsZeno groupBiomedical advanced researchMeiji seika pharma coAdministration for strategic preparednessDevelopment authoritySpero therapeutics incDrug administration

Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections

CAMBRIDGE, Mass., Jan. 02, 2024 Spero Therapeutics, Inc. , a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high.

United kingdomUnited statesSath shuklaLora grassilliTed jenkinsExchange commissionZeno groupSpero therapeutics incDevelopment authorityHealth media relationsDrug administrationMeiji seika pharma coAdministration for strategic preparednessHuman servicesGlobenewswire incTebipenem hbr research

Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating

CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas

United kingdomUnited statesLora grassilliTed jenkinsSath shuklaHealth media relationsBiomedical advanced researchTebipenem hbr researchAdministration for strategic preparednessExchange commissionZeno groupDrug administrationDevelopment authorityHuman servicesSpero therapeutics incMeiji seika pharma co